QLY Biotech Group Corp.
CIK:0001787123|SEC Filings
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Feb. 28, 2023 |
Feb. 28, 2022 |
Feb. 28, 2023 |
Feb. 28, 2022 |
|
| CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | ||||
| REVENUES | $ 0 | $ 0 | $ 0 | $ 0 |
| COST OF REVENUES | 0 | 0 | 0 | 0 |
| GROSS PROFIT | 0 | 0 | 0 | 0 |
| GENERAL & ADMINISTRATIVE EXPENSES | 11,620 | 1,755 | 20,788 | 5,967 |
| LOSS BEFORE INCOME TAX | (11,620) | (1,755) | (20,788) | (5,967) |
| Income tax expense | 0 | 0 | 0 | |
| NET LOSS | (11,620) | (1,755) | (20,788) | (5,967) |
| Other comprehensive income: | ||||
| - Foreign currency translation adjustment | 0 | 0 | 0 | |
| COMPREHENSIVE LOSS | $ (11,620) | $ (1,755) | $ (20,788) | $ (5,976) |
| Net loss per share- Basic and diluted | $ (0.00) | $ 0.00 | $ (0.01) | $ 0.00 |
| Weighted Average Number of shares outstanding- Basic and diluted | 3,895,000 | 3,895,000 | 3,895,000 | 3,895,000 |
CONDENSED BALANCE SHEETS - USD ($) |
Feb. 28, 2023 |
Aug. 31, 2022 |
|---|---|---|
| ASSETS | ||
| TOTAL ASSETS | $ 0 | $ 0 |
| CURRENT LIABILITIES | ||
| Accrued liabilities | 4,851 | 0 |
| Amount due to a director | 14,817 | 0 |
| Total current liabilities | 19,668 | 0 |
| TOTAL LIABILITIES | 19,668 | 0 |
| STOCKHOLDERS' DEFICIT | ||
| Common stock, $0.001 par value, 1,000,000,000 shares authorized, 3,895,000 shares issued and outstanding as of February 28, 2023 and August 31, 2022, respectively | 3,895 | 3,895 |
| Additional paid-in capital | 47,150 | 46,030 |
| Accumulated deficit | (70,713) | (49,925) |
| TOTAL STOCKHOLDERS' DEFICIT | (19,668) | 0 |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 0 | $ 0 |